2001 to 2012: After September 11 · Health, Food & Regulators

Purdue Pharma, the FDA's OxyContin Label, DEA Production Quotas, and 806,000 Opioid Deaths

Period covered: 1995 to 2026 · 9 sources

Summary

In 1995 the Food and Drug Administration approved OxyContin with a label saying its slow release was believed to reduce the abuse liability of the drug, a claim the agency later admitted it had no data for. The company pleaded guilty in 2007 to marketing it as less addictive than it was, and again in 2020 to defrauding the government and paying kickbacks. Between 2002 and 2013 the Drug Enforcement Administration raised the amount of oxycodone that could legally be made in the country by more than 400 percent while the deaths rose, and did not cut it until 2017. About 806,000 Americans died of opioid overdoses between 1999 and 2023. In April 2026 a federal judge, sentencing the company, told the victims that their government had failed them.

The opioid epidemic is usually told as the story of a company. It is also the story of three federal agencies: the one that approved the drug, the one that set how much of it could be made, and the one that prosecuted the company twice and let it keep selling.

The label

The Food and Drug Administration approved OxyContin in December 1995. Its active ingredient, oxycodone, had been in use for decades; what was new was a coating that released it over twelve hours. The label the agency approved stated that delayed absorption, as provided by OxyContin tablets, is believed to reduce the abuse liability of a drug. The Government Accountability Office reported in December 2003 that the agency had later concluded it had no data to support that statement. The company built its sales campaign on the sentence. It doubled its sales force, paid bonuses tied to prescriptions, and, by 2001, had the most prescribed brand name narcotic for moderate to severe pain in the country. Reports of abuse and diversion began in 2000.

The first plea

On May 10, 2007 the Purdue Frederick Company pleaded guilty in federal court in Virginia to a felony: misbranding OxyContin with the intent to defraud and mislead. The government's statement of the case was that Purdue fraudulently marketed OxyContin by falsely claiming that it was less addictive, less subject to abuse, and less likely to cause withdrawal symptoms than other pain medications when there was no medical research to support these claims, and that it had trained its sales representatives to say so while its own market research showed the drug's biggest negative was its abuse potential. The company paid $634.5 million. Its president, its chief lawyer, and its former chief medical officer pleaded guilty to misdemeanors and paid $34.5 million among them. None went to prison. The company kept its license, and OxyContin kept selling.

The quota

The Drug Enforcement Administration sets, each year, the total amount of each controlled substance that may be manufactured in the United States. The Justice Department's inspector general reviewed what the agency did with that power and reported in September 2019. The 2013 quota for oxycodone was over 400 percent of the 2002 quota, up from 34,482 kilograms to 153,750. The agency did not significantly reduce it until 2017, when a 25 percent cut was ordered. Over the same years the inspector general found that the agency was slow to respond to the significant increase in the use and diversion of opioids since 2000, as overdose deaths rose an average of 8 percent a year from 1999 to 2013 and then 71 percent a year from 2013 to 2017, and that it cut its use of immediate suspension orders, its strongest tool against distributors, by more than 80 percent between 2010 and 2017, from 38 a year to six.

The second plea

On November 24, 2020 Purdue Pharma pleaded guilty to three felonies: conspiracy to defraud the United States and violate the food and drug law, and two conspiracies to violate the anti kickback statute. It admitted that it had marketed its opioids to more than 100 doctors it had reason to believe were diverting them to abusers, that it had given the DEA misleading information to inflate its manufacturing quota, and that it had paid kickbacks to doctors and to a medical records company to push prescriptions. The penalties totaled $8.3 billion on paper: a $3.544 billion fine, $2 billion in forfeiture, and $2.8 billion in civil claims. The company was in bankruptcy and most of it was never expected to be paid. The Sackler family, which owned the company, settled civil claims for $225 million.

The bankruptcy and the sentence

The bankruptcy plan that lets the Sackler family pay up to $7 billion over fifteen years and give up the company, in exchange for releases from the claims of creditors who choose to accept, was confirmed on November 18, 2025 after the Supreme Court had struck down an earlier version in June 2024 for releasing the family without the creditors' consent. About $7.4 billion goes to the states, local governments, and an $865 million fund for individuals. On April 29, 2026 a federal judge sentenced the company on its 2020 plea to $5.5 billion in fines and penalties, of which the government will actually collect $225 million, with the rest left for the creditors. Her words to the people in the courtroom were that their government had failed them, and that the inadequacy of what the law can offer had to be plainly stated.

The Official Count

The Centers for Disease Control and Prevention counts the epidemic in three waves: prescription opioids from the 1990s, heroin from 2010, and illegally made fentanyl from 2013. Its figure is that from 1999 to 2023 approximately 806,000 people died from an opioid overdose. Drug overdose deaths of all kinds were 105,007 in 2023, fell to 79,384 in 2024, and by the provisional count released May 13, 2026 fell again to about 69,973 in 2025. The decline is real. It began twenty eight years after the label was approved.

← 2001 to 2012

Primary Sources (9)

Documents, court filings, official reports, and broadcasts cited in this report.

2003
General Accounting Office. The 1995 approval, the label's claim that delayed absorption was believed to reduce abuse liability, the FDA's later finding of no data, and the marketing.
2007
United States Attorney's Office, Western District of Virginia. Felony misbranding with intent to defraud and mislead; $634.5 million; three executives' misdemeanor pleas and $34.5 million; the false claims about addiction.
2019
U.S. Department of Justice, Office of the Inspector General. The oxycodone quota over 400 percent of 2002 by 2013; no significant reduction until 2017; DEA slow to respond; immediate suspension orders cut more than 80 percent.
2020
U.S. Department of Justice. Three felonies; $8.3 billion in penalties on paper; marketing to more than 100 diverting doctors; misleading the DEA on quotas; kickbacks; the Sacklers' $225 million civil settlement.
2025
California Lawyers Association. Confirmed November 18, 2025 by Judge Lane; up to $7 billion from the family over 15 years; about $7.4 billion to creditors; opt in releases after the Supreme Court's 2024 decision.
2026
National Center for Health Statistics. 105,007 deaths in 2023 and 79,384 in 2024.
2026
Insurance Journal. The $5.5 billion sentence, $225 million to be collected; the $865 million fund; the judge's words: your government failed you.
2026
National Center for Health Statistics. An estimated 69,973 overdose deaths in 2025, down almost 14 percent from 81,313 in 2024.
2026
Centers for Disease Control and Prevention. Approximately 806,000 opioid overdose deaths 1999 to 2023; the three waves.

Documented Records (3)

Chronological entries extracted from the primary sources above.

2007
1995 to 2007
The FDA approved OxyContin in 1995 with a label saying delayed absorption was believed to reduce abuse liability, a claim it later found it had no data for. On May 10, 2007 the maker pleaded guilty to felony misbranding with intent to defraud and mislead, admitting it had trained its sales force to call the drug less addictive and less subject to abuse with no research to support it, and paid $634.5 million. Three executives pleaded to misdemeanors. The company kept selling.
“Purdue fraudulently marketed OxyContin by falsely claiming that OxyContin was less addictive, less subject to abuse, and less likely to cause withdrawal symptoms than other pain medications when there was no medical research to support these claims.”
Food and Drug Administration; Purdue Frederick; its executives. Violates: The food and drug law. Pleaded guilty; no prison.. Source: The Purdue Frederick Company, Inc. and Top Executives Plead Guilty to Misbranding OxyContin; Will Pay Over $600 Million, United States Attorney's Office, Western District of Virginia
2019
2002 to 2017, reported September 2019
The DEA raised the national production quota for oxycodone from 34,482 kilograms in 2002 to 153,750 in 2013, over 400 percent, while overdose deaths rose 8 percent a year and then 71 percent a year, and did not significantly cut it until 2017. It reduced its immediate suspension orders against distributors by more than 80 percent between 2010 and 2017.
“DEA was slow to respond to the significant increase in the use and diversion of opioids since 2000.”
Drug Enforcement Administration. Violates: The Controlled Substances Act's purpose of preventing diversion. Found by the inspector general to have been slow.. Source: Review of the Drug Enforcement Administration's Regulatory and Enforcement Efforts to Control the Diversion of Opioids, U.S. Department of Justice, Office of the Inspector General
2026
November 24, 2020 to April 29, 2026
Purdue pleaded guilty to three felonies, including marketing to more than 100 doctors it believed were diverting its drugs and misleading the DEA to raise its quota; the $8.3 billion penalty was mostly uncollectable in bankruptcy. The plan confirmed November 18, 2025 has the Sackler family pay up to $7 billion over fifteen years. At sentencing on April 29, 2026 the judge told the victims their government had failed them. The CDC counts about 806,000 opioid overdose deaths from 1999 to 2023.
“Your government failed you. The inadequacy of what the law can offer today must be plainly stated.”
Purdue Pharma; the Sackler family; the Department of Justice. Violates: Federal fraud and kickback law. Guilty; no one imprisoned.. Source: Purdue Pharma Receives $5.5B Sentence, Paving Way for Opioid Settlement, Insurance Journal

Timeline Events (6)

Dated events from this investigation in the site timeline.

April 29, 2026
Judge sentencing Purdue: your government failed you
$5.5 billion on paper; $225 million to be collected.
November 18, 2025
Purdue bankruptcy plan confirmed; Sacklers to pay up to $7 billion over 15 years
Opt in releases after the Supreme Court struck the first plan.
November 24, 2020
Purdue pleads guilty to three felonies
$8.3 billion on paper, mostly uncollectable.
May 10, 2007
Purdue pleads guilty to misbranding OxyContin
$634.5 million; no prison; sales continue.
December 1995
FDA approves OxyContin with an abuse claim it had no data for
The sentence the sales campaign was built on.
Purdue Pharma, the FDA's OxyContin Label, DEA Production Quotas, and 806,000 Opioid Deaths | Spirit of '76